 Hello, I am Wendel Kautraels and I am the CEO of Selector Biosciences. Selector has a unique nanoparticle technology, a platform that allows the design and optimization of products, those are vaccines and immunotherapeutics, that will instruct the immune system to address different diseases with high medical need that lack good treatment today. We believe that this technology has the potential to herald a new generation of vaccine applications while also taking existing vaccines to unprecedented levels of effectiveness. Selector is unique by its people, by its scientists in Boston in Moscow, but also by its founders and investors. Selector is unique by its global approach. Our subsidiary in Moscow provides an additional dimension by opening our view and reach early and better into emerging markets. Selector follows a completely novel approach. By combining nanoparticle technology and immunology, we were inspired by the fact that virus can actually be effectively mimicked by Selector's propriety nanoparticles. The immune system is very powerful and will react in very specific ways. Our products don't act directly on the culprit of disease, but instruct the immune system to do that work, harnessing the body's own power. In our nanoparticles we can instruct the immune system to make antibodies or killer T-cells. That's a kind of white blood cells to fight disease. Examples are infections and cancer. We have research programs in, for instance, malaria and in melanoma, and in this category we also have a product under development for smoking cessation. But we can actually do more and better. We can also instruct the immune system to stop reacting when otherwise it would cause disease. Examples are autoimmune diseases, allergies, transplant rejection, and also a neutralization of therapies with biologicals, such as in orphan disease. In this category we already work in the field of type 1 diabetes, food allergies, and hemophilia. So in summary, the combination of nanoparticle technology together with a better understanding of how the immune system works allows us to tackle disease areas with high medical need. But there is still a lot of work to be done in the lab and afterwards in clinical testing, and we are ready to continue that work. Selecta will have a major impact on the world in two significant ways. First, bring answers to very important disease that currently have no good available treatment. A better vaccine for malaria, prevent neutralization of orphan disease treatments, a vaccine for type 1 diabetes, and a vaccine for smoking cessation. Secondly, we can change the paradigm of vaccine manufacturing, from expensive and difficult to transfer fermentation technologies to a synthetic manufacturing process providing more stable products with easier geographical distribution. The latter is not only a scientific and technical matter, but often also a geopolitical matter. Because of these geopolitical aspects, we at Selecta are delighted and honored to be a World Economic Forum Tech pioneer, because it will help us to achieve the exposure that may be required to bring our products to patients around the world more expeditiously.